GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Discussion] the endpoint advice in here is 3 years out of date — 51 comments in the full submission. View in context.
3.5k
c/trialwatch·submitted 2 years ago by u/rina_sobczak

[Discussion] the endpoint advice in here is 3 years out of date

Discussionbranch of 8 comments

Thinking out loud about this: the endpoint advice in here is 3 years out of date. 3 years — those are the numbers, and they are the ones I am willing to defend. Discontinuation rates are a tolerability result. A trial with a strong efficacy number and heavy discontinuation is telling you two things and people only…

Read the full submission and all 51 comments →

This branch

8 comments, started 2 years ago
u/sten_palacios333 points·2 years ago

Relative risk reduction without the baseline rate is uninterpretable. A large relative reduction on a small absolute risk is a small absolute benefit.

replysharereportpermalink
u/alcohol_aversion91 points·2 years ago

This. Intention-to-treat versus completer analysis routinely moves the headline by several points.

replysharereportpermalink
u/annika_fonseca44 points·2 years ago

How long was the randomised phase before any extension?

replysharereportpermalink
u/trialwatch_theoMOD172 points·2 years ago

Retitled: the original quoted a diabetes endpoint as an obesity result.

replysharereportpermalink
u/nikhil_lindqvist45 points·2 years ago

What did the confidence interval look like?

replysharereportpermalink
u/zaid_roos36 points·2 years ago·edited

Correction: SURMOUNT is the obesity programme and SURPASS is the diabetes one. The figure you quoted belongs to the other one.

replysharereportpermalink
u/renal_outcomes_rnephro-curious193 points·2 years ago

trial populations get support that nobody on this board gets

replysharereportpermalink
load more comments (1) →

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Janoshik Analytical

Independent HPLC and mass spec. The number you get is the number they found.

janoshik.comSponsored

GL Biochem (Shanghai)

Custom peptides and amino acids direct from the manufacturer since 1998. ISO 9001 / cGMP. Batch COA every order.

glbiochem.net
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →